Publications by authors named "M Nadri"
Dengue is one of the most prevalent viruses transmitted by the Aedes aegypti mosquitoes. Currently, no specific medication is available to treat dengue diseases. The NS2B-NS3 protease is vital during post-translational processing, which is a key target in this study.
View Article and Find Full Text PDFArticle Synopsis
- * In a study of 982 cancer patients from 2020 to 2023, most received the initial vaccine and one booster, but the uptake for the newer bivalent booster was significantly low at only 30.1%.
- * Despite low booster rates, nearly all participants showed improved immune responses after receiving at least two boosters, and those who got boosted had a lower risk of mortality, highlighting the need for better strategies to encourage vaccinations among this vulnerable group.
Article Synopsis
- SARS-CoV-2 can spread from asymptomatic individuals, posing a greater risk to cancer patients who frequently visit healthcare facilities and are more vulnerable to severe COVID-19 outcomes.* -
- A study of lung cancer patients revealed that over half of those with evidence of SARS-CoV-2 infection were asymptomatic at diagnosis, and a significant number were never clinically diagnosed.* -
- The findings indicate that older patients and those with early-stage lung cancer are more likely to have asymptomatic infections, highlighting the need for continued preventive measures in high-risk populations.*
The rise in dengue cases in tropical and sub-tropical areas has become a significant health concern. At present, there is no definitive cure for dengue fever, which underscores the importance of identifying potent inhibitors. Dengue NS2B-NS3 protease is the prime drug target due to its vital function for replication.
View Article and Find Full Text PDFArticle Synopsis
- - Patients with cancer have a higher risk of severe outcomes from COVID-19 and show weakened immune responses to vaccines, highlighting the importance of regular boosters in this group
- - A study of 982 cancer patients found high initiation of vaccination (92.3% received the primary vaccine) but lower uptake of boosters, especially among younger patients and racial minorities
- - Receiving multiple booster shots significantly increased antibody levels and T-cell responses, leading to a lower risk of death, indicating the need for improved strategies to boost vaccination rates among high-risk cancer patients